Categories: News

Integral Molecular Doubles Antibody Characterization Capacity Within Philadelphia’s Science Center

PHILADELPHIA, April 16, 2019 /PRNewswire/ — Integral Molecular, the industry leader in membrane protein solutions, today announced the expansion of its two proprietary antibody characterization platforms, Shotgun Mutagenesis Epitope Mapping and the Membrane Proteome Array (MPA). Integral Molecular recently acquired office and laboratory space, which enabled the company to double its antibody characterization capabilities.

“Businesses like Integral Molecular are creating jobs and contributing to the vibrancy of Philadelphia’s biosector. We’re thrilled that Integral Molecular has chosen to start, grow, and expand right here at uCity Square,” says Steve Zarrilli, President & CEO of University City Science Center. “Integral Molecular’s trajectory exemplifies the services and support offered by the Science Center and facilities available at uCity Square.”

The expansion is being driven by recent MPA Target Discovery partnerships and a surge of Shotgun Mutagenesis Epitope Mapping projects, prompting the need for additional space and personnel.

“Integral Molecular is in an exciting growth phase where we’re expanding our teams, launching new products, and reaching new markets,” says Ben Doranz, President and CEO of Integral Molecular. “To achieve these goals, we’re dedicating additional resources to antibody characterization, a key component of our suite of membrane protein solutions.”

About Integral Molecular

Integral Molecular (www.integralmolecular.com) is the industry leader in membrane protein solutions, with a pipeline of therapeutic antibodies against GPCRs, ion channels, transporters, and immuno-oncology targets. Built on the company’s extensive experience optimizing membrane proteins, Integral Molecular’s technology suite enables the isolation, characterization, and engineering of MAbs against otherwise intractable targets. The company currently has therapeutic programs focused on cancer, pain, immunity, and metabolic diseases.

Contact:
Integral Molecular, Inc.
Ben Doranz, PhD, President and CEO                     
215-966-6061
info@integralmolecular.com 
www.integralmolecular.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/integral-molecular-doubles-antibody-characterization-capacity-within-philadelphias-science-center-300832409.html

SOURCE Integral Molecular

Staff

Recent Posts

72 Million American Women Have Skipped or Delayed Vital Screenings

New Survey Reveals Women Struggle to Prioritize Their HealthMARLBOROUGH, Mass.--(BUSINESS WIRE)--$HOLX #HGWHI--Millions of women in…

2 hours ago

New-Generation Slow-Dissolving Chlorine Tablets Provide Superior Pool Protection

Introducing 3Chlorine New-Generation Chlorine Tablets to Provide Unparalleled Pool Maintenance and SanitationRANCHO MIRAGE, CA /…

2 hours ago

Invitation to Cosmo’s Half-Year 2024 Webcast on 24 July 2024

Dublin, Ireland--(Newsfile Corp. - July 9, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43)…

6 hours ago

Rosen Law Firm Urges SeaStar Medical Holding Corporation (ICU, ICUCW) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder…

8 hours ago

Best Rated San Antonio Plastic Surgeons for 2024 (Q1) Research Report Released by Doctor Marketing, MD

The Review Growth Index™ (RGI™) by Doctor Marketing, MD™ releases the researched list of Top…

8 hours ago